T Koudstaal1, D van Uden1, J A C van Hulst1, P Heukels1, I M Bergen1, L W Geenen2, V J M Baggen2, A E van den Bosch2, L M van den Toorn1, P P Chandoesing1, M Kool1, E Boersma2,3, R W Hendriks1, K A Boomars4. 1. Department of Pulmonary Medicine, Erasmus MC, University Medical Center, Doctor Molewaterplein 40, 3015 GD, Rotterdam, The Netherlands. 2. Department of Cardiology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands. 3. Department of Clinical Epidemiology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands. 4. Department of Pulmonary Medicine, Erasmus MC, University Medical Center, Doctor Molewaterplein 40, 3015 GD, Rotterdam, The Netherlands. k.boomars@erasmusmc.nl.
Abstract
BACKGROUND: Recent studies have provided evidence for an important contribution of the immune system in the pathophysiology of pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH). In this report, we investigated whether the inflammatory profile of pulmonary hypertension patients changes over time and correlates with patient WHO subgroups or survival. METHODS: 50 PAH patients (16 idiopathic (I)PAH, 24 Connective Tissue Disease (CTD)-PAH and 10 Congenital Heart Disease (CHD)-PAH), 37 CTEPH patients and 18 healthy controls (HCs) were included in the study. Plasma inflammatory markers at baseline and after 1-year follow-up were measured using ELISAs. Subsequently, correlations with hemodynamic parameters and survival were explored and data sets were subjected to unbiased multivariate analyses. RESULTS: At diagnosis, we found that plasma levels of interleukin-6 (IL-6) and the chemokines (C-X3-C) motif legend CXCL9 and CXCL13 in CTD-PAH patients were significantly increased, compared with HCs. In idiopathic PAH patients the levels of tumor growth factor-β (TGFβ), IL-10 and CXCL9 were elevated, compared with HCs. The increased CXCL9 and IL-8 concentrations in CETPH patients correlated significantly with decreased survival, suggesting that CXCL9 and IL-8 may be prognostic markers. After one year of treatment, IL-10, CXCL13 and TGFβ levels changed significantly in the PAH subgroups and CTEPH patients. Unbiased multivariate analysis revealed clustering of PH patients based on inflammatory mediators and clinical parameters, but did not separate the WHO subgroups. Importantly, these multivariate analyses separated patients with < 3 years and > 3 years survival, in particular when inflammatory mediators were combined with clinical parameters. DISCUSSION: Our study revealed elevated plasma levels of inflammatory mediators in different PAH subgroups and CTEPH at baseline and at 1-year follow-up, whereby CXCL9 and IL-8 may prove to be prognostic markers for CTEPH patients. While this study is exploratory and hypothesis generating, our data indicate an important role for IL-8 and CXCL9 in CHD and CTEPH patients considering the increased plasma levels and the observed correlation with survival. CONCLUSION: In conclusion, our studies identified an inflammatory signature that clustered PH patients into WHO classification-independent subgroups that correlated with patient survival.
BACKGROUND: Recent studies have provided evidence for an important contribution of the immune system in the pathophysiology of pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH). In this report, we investigated whether the inflammatory profile of pulmonary hypertensionpatients changes over time and correlates with patient WHO subgroups or survival. METHODS: 50 PAH patients (16 idiopathic (I)PAH, 24 Connective Tissue Disease (CTD)-PAH and 10 Congenital Heart Disease (CHD)-PAH), 37 CTEPHpatients and 18 healthy controls (HCs) were included in the study. Plasma inflammatory markers at baseline and after 1-year follow-up were measured using ELISAs. Subsequently, correlations with hemodynamic parameters and survival were explored and data sets were subjected to unbiased multivariate analyses. RESULTS: At diagnosis, we found that plasma levels of interleukin-6 (IL-6) and the chemokines (C-X3-C) motif legend CXCL9 and CXCL13 in CTD-PAH patients were significantly increased, compared with HCs. In idiopathic PAH patients the levels of tumor growth factor-β (TGFβ), IL-10 and CXCL9 were elevated, compared with HCs. The increased CXCL9 and IL-8 concentrations in CETPH patients correlated significantly with decreased survival, suggesting that CXCL9 and IL-8 may be prognostic markers. After one year of treatment, IL-10, CXCL13 and TGFβ levels changed significantly in the PAH subgroups and CTEPHpatients. Unbiased multivariate analysis revealed clustering of PHpatients based on inflammatory mediators and clinical parameters, but did not separate the WHO subgroups. Importantly, these multivariate analyses separated patients with < 3 years and > 3 years survival, in particular when inflammatory mediators were combined with clinical parameters. DISCUSSION: Our study revealed elevated plasma levels of inflammatory mediators in different PAH subgroups and CTEPH at baseline and at 1-year follow-up, whereby CXCL9 and IL-8 may prove to be prognostic markers for CTEPHpatients. While this study is exploratory and hypothesis generating, our data indicate an important role for IL-8 and CXCL9 in CHD and CTEPHpatients considering the increased plasma levels and the observed correlation with survival. CONCLUSION: In conclusion, our studies identified an inflammatory signature that clustered PHpatients into WHO classification-independent subgroups that correlated with patient survival.
Entities:
Keywords:
Biomarkers; Chronic thromboembolic pulmonary hypertension; Inflammation and immunity; Inflammatory cytokines; Pulmonary arterial hypertension; Pulmonary hypertension; Survival and prognosis
Authors: Nazzareno Galiè; Marc Humbert; Jean-Luc Vachiery; Simon Gibbs; Irene Lang; Adam Torbicki; Gérald Simonneau; Andrew Peacock; Anton Vonk Noordegraaf; Maurice Beghetti; Ardeschir Ghofrani; Miguel Angel Gomez Sanchez; Georg Hansmann; Walter Klepetko; Patrizio Lancellotti; Marco Matucci; Theresa McDonagh; Luc A Pierard; Pedro T Trindade; Maurizio Zompatori; Marius Hoeper Journal: Eur Respir J Date: 2015-08-29 Impact factor: 16.671
Authors: Raymond L Benza; Dave P Miller; Robyn J Barst; David B Badesch; Adaani E Frost; Michael D McGoon Journal: Chest Date: 2012-08 Impact factor: 9.410
Authors: Göran Rådegran; Barbro Kjellström; Björn Ekmehag; Flemming Larsen; Bengt Rundqvist; Sofia Berg Blomquist; Carola Gustafsson; Roger Hesselstrand; Monica Karlsson; Björn Kornhall; Magnus Nisell; Liselotte Persson; Henrik Ryftenius; Maria Selin; Bengt Ullman; Kent Wall; Gerhard Wikström; Maria Willehadson; Kjell Jansson Journal: Scand Cardiovasc J Date: 2016-06-14 Impact factor: 1.589
Authors: Benoît Ranchoux; Lloyd D Harvey; Ramon J Ayon; Aleksandra Babicheva; Sebastien Bonnet; Stephen Y Chan; Jason X-J Yuan; Vinicio de Jesus Perez Journal: Pulm Circ Date: 2017-12-28 Impact factor: 3.017
Authors: Syed Rehan Quadery; Andrew J Swift; Catherine G Billings; Alfred A R Thompson; Charles A Elliot; Judith Hurdman; Athanasios Charalampopoulos; Ian Sabroe; Iain J Armstrong; Neil Hamilton; Paul Sephton; Sian Garrad; Joanna Pepke-Zaba; David P Jenkins; Nicholas Screaton; Alexander M Rothman; Allan Lawrie; Trevor Cleveland; Steven Thomas; Smitha Rajaram; Catherine Hill; Christine Davies; Christopher S Johns; Jim M Wild; Robin Condliffe; David G Kiely Journal: Eur Respir J Date: 2018-09-16 Impact factor: 33.795
Authors: Zongye Cai; Siyu Tian; Theo Klein; Ly Tu; Laurie W Geenen; Thomas Koudstaal; Annemien E van den Bosch; Yolanda B de Rijke; Irwin K M Reiss; Eric Boersma; Claude van der Ley; Martijn Van Faassen; Ido Kema; Dirk J Duncker; Karin A Boomars; Karin Tran-Lundmark; Christophe Guignabert; Daphne Merkus Journal: Sci Rep Date: 2022-07-19 Impact factor: 4.996
Authors: Denise van Uden; Thomas Koudstaal; Jennifer A C van Hulst; Madelief Vink; Menno van Nimwegen; Leon M van den Toorn; Prewesh P Chandoesing; Annemien E van den Bosch; Mirjam Kool; Rudi W Hendriks; Karin A Boomars Journal: Int J Mol Sci Date: 2022-06-10 Impact factor: 6.208
Authors: Denise van Uden; Thomas Koudstaal; Jennifer A C van Hulst; Thierry P P van den Bosch; Madelief Vink; Ingrid M Bergen; Karishma A Lila; Annemien E van den Bosch; Paul Bresser; Mirjam Kool; Jan H von der Thüsen; Rudi W Hendriks; Karin A Boomars Journal: Front Immunol Date: 2022-04-27 Impact factor: 8.786
Authors: Wojciech Magoń; Jakub Stępniewski; Marcin Waligóra; Kamil Jonas; Roman Przybylski; Piotr Podolec; Grzegorz Kopeć Journal: Cells Date: 2022-04-29 Impact factor: 7.666